Related Experiment Videos
Japanese ovarian trials: focus on irinotecan
Toru Sugiyama1, Michiaki Yakushiji, Kazunori Ochiai
1Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan. sugiyama@iwate-med.ac.jp
Oncology (Williston Park, N.Y.)
|June 13, 2003
Abstract:
Irinotecan (CPT-11, Camptosar) has achieved a response rate of 23.6% in recurrent ovarian cancer. Irinotecan/cisplatin combination chemotherapy has shown a response rate of 33% in platinum-resistant ovarian cancer, and 76% when used as the initial regimen for ovarian cancer. Regarding dose-limiting toxicity, although neutropenia and diarrhea were observed, diarrhea was thought to cause no remarkable problems in the combination regimen examined. Based on these results, irinotecan is considered to be a useful drug in chemotherapy for ovarian cancer.